Xenon Pharmaceuticals (XENE) reported late Thursday a Q1 net loss of $1.17 per diluted share, compared with a loss of $0.83 a year earlier.
Based on current operating plans, Xenon said it expects having sufficient cash to fund operations into 2029.
Xenon Pharmaceuticals (XENE) reported late Thursday a Q1 net loss of $1.17 per diluted share, compared with a loss of $0.83 a year earlier.
Based on current operating plans, Xenon said it expects having sufficient cash to fund operations into 2029.
Comments